Low-dose Bevacizumab Decreases Ocular Hypotensive Effect of Angiotensin II in Sprague Dawley Rats.

Janusz SkrzypeckiK CiepiaszukM Gawryś-Kopczyńska

Published in: Current eye research (2020)

We found that low-dose bevacizumab interferes with IOP-lowering properties of angiotensin II. This effect might be related to increased expression of angiotensin II receptors in the anterior segment of the eye.

Keyphrases

angiotensin ii
low dose
angiotensin converting enzyme
vascular smooth muscle cells
high dose
metastatic colorectal cancer
poor prognosis
binding protein